肿瘤血管超选择性化疗栓塞后恶性鼻咽癌患者治疗的结果.
##article.numberofdownloads## 156
##article.numberofviews## 179
pdf (Русский)

关键词

化学栓塞
局部晚期鼻咽癌
头颈癌

How to Cite

Митрофанов, А., Раджабова, З., Раджабов, С., Котов, М., Пономарева, О., Гиршович, М., Костромина, Е., & Клименко, В. (2023). 肿瘤血管超选择性化疗栓塞后恶性鼻咽癌患者治疗的结果. VOPROSY ONKOLOGII, 69(3), 487–496. https://doi.org/10.37469/0507-3758-2023-69-3-487-496

摘要

目标。 评价肿瘤血管超选择性化学栓塞作为鼻咽局部晚期恶性肿瘤联合治疗阶段的临床意义。
方法。 一项前瞻性纳入的回顾性研究包括71名在2012年至2021年期间接受治疗的NC cT3-4,N0-3,M0患者。 化学栓塞+CRT组(CE+CRT,研究组)包括接受肿瘤血管超选择性化学栓塞第一阶段随后联合治疗(同时CRT随后辅助化疗(AC)的患者。 CRT组(对照组)包括接受联合治疗的患者:同时CLT随后是AC。 根据早期和晚期放射并发症的RTOG评估量表进行并发症的评估,使用Recist1.1标准评估对治疗的反应。
结果。 研究中包括71名患者。 平均年龄为47岁(IQR:20-60)。 两组无进展生存的平均随访时间为29个月(IQR12–50个月)。 1年后的无进展生存率在CE+CRT组中为88.7%(95%CI=69.0–96.2),在CRT组中为76.5%(95%CI=60.8-86.6)。 CE+CRT组的两年无复发生存率为79.6%(95%CI=57.5–91.0)和71.6%(95%CI=55.4–82.8)。 CE+CRT组的一年期总生存率为96.3%(95%CI=76.5–99.5),CRT组为83.7%(95%CI=68.9-91.9)。 总体两年生存率分别为87.3%(95%CI=65.4–95.8)和76.5%(95%CI=60.6-86.6)。 在CRT组中,51.2%的患者发生2级粘膜炎,而CE+CRT组患者为35.7%(p<0.01)。 在影响无复发生存的因素的多变量分析中,男性性别是影响无复发生存的独立临床因素。
结论。 我们的研究结果表明,鼻咽恶性肿瘤血管的化疗栓塞在局部晚期鼻咽肿瘤患者中提供了可接受的反应率,并允许全剂量化疗,根治性剂量的远程化学放 它还提供与标准疗法相当的无复发和总体生存率。 然而,需要进一步的研究来评估治疗后鼻咽肿瘤的局部控制。

https://doi.org/10.37469/0507-3758-2023-69-3-487-496
##article.numberofdownloads## 156
##article.numberofviews## 179
pdf (Русский)

参考

Гранов А.М. Интервенционная радиология в онкологии: пути развития и технологии. А.М. Гранов, М.И. Давыдов. СПб.: Фолиант, 2013. 560 с [Granov A.M. Interventional radiology in oncology: ways of development and technologies. A.M.Granov, M.I. Davydov. SPb.: Foliant, 2013. 560 p. [In Russ]

Мерабишвили В.М. Состояние онкологической помощи в России. Аналитические показатели: одногодичная летальность (популяционное исследование на уровне федерального округа) / В.М. Мерабишвили // Вопросы онкологии. – 2022. – Т. 68, № 1. – С. 38-47. [V.M. Merabishvili. The state of cancer care in Russia. Analytical indicators: one-year mortality (population study at the federal district level). Voprosy oncologii. 2022; 68(1): 38-47.[In Russ]

Таразов П. Г. Методы регионарной терапии опухолей различных локализаций. П. Г. Таразов. Практическая онкология. Том 16. No 4. 2015. С. 131–139. [Tarazov P.G. Methods of regional therapy of tumors of various localizations. Practical oncology. 2015; 16(4): 131-139.[In Russ]

Химиоперфузионное лечение злокачественных опухолей : Руководство для врачей / А. М. Беляев, О. В. Леонтьев, М. В. Рогачев [и др.] ; Под редакцией А.М. Беляева, О.В. Леонтьева, М.В. Рогачева. – Санкт-Петербург : Общество с ограниченной ответственностью "Издательство "СпецЛит", 2018. – 286 с. [Khimioperfuzionnoe lechenie zlokachestvennykh opukholei : Rukovodstvo dlia vrachei / A. M. Beliaev, O. V. Leont'ev, M. V. Rogachev [et al.]; Pod redaktsiei A.M. Beliaeva, O.V. Leont'eva, M.V. Rogacheva. Sankt-Peterburg : Obshchestvo s ogranichennoi otvetstvennost'iu "Izdatel'stvo "SpetsLit", 2018. 286 p.[In Russ]

A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. / Y. P. Chen, Z. X. Wang, L. Chen [и др.] // Annals of oncology : official journal of the European Society for Medical Oncology. – 2015. – Т. 26, № 1. – С. 205-211.

Active and Passive Smoking and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China. / E.T. Chang, Z. Liu, A. Hildesheim [и др.] // American journal of epidemiology. – 2017. – Т. 185, № 12. – С. 1272-1280.

Angiogenesis in head and neck tumor. / Y. Mikami, M. Tsukuda, I. Mochimatsu [и др.] // Nihon Jibiinkoka Gakkai Kaiho. – 1993. – № 4. – С. 645-650.

Cancer vascularization: implications in radiotherapy? / M.I. Koukourakis, A. Giatromanolaki, E. Sivridis, I. Fezoulidis // International Journal of Radiation Oncology - Biology - Physics.. – 2000. – № 2. – С. 545-553.

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. / M. Al-Sarraf, M. LeBlanc, P.G. Giri [и др.] // Journal of clinical oncology : official journal of the American Society of Clinical Oncology. – 1998. – Т. 16, № 4. – С. 1310-1317.

Clinical and histopathological results after local chemoembolization of oral and oropharyngeal carcinoma - comparison with intra-arterial chemoperfusion in Germany / S. Rohde, B. Turowski, J. Berkefeld, AF Kovács // RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.. – 2006. – Т. 178, № 10. – С. 979-986.

Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. / L. Chen, C. S. Hu, X. Z. Chen [и др.] // The Lancet. Oncology. – 2012. – Т. 2, № 13. – С. 163-171.

Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up. / L. Wang, Z. Wu, W. Cheng [и др.] // Radiation oncology. – 2021. – Т. 16, № 1. – С. 215.

Etiological factors of nasopharyngeal carcinoma. / S.W. Tsao, Y.L. Yip, C.M. Tsang [и др.] // Oral oncology. – 2014. – Т. 50, № 5. – С. 330-338.

Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. / X. Guo, R.C. Johnson, H. Deng [и др.] // International journal of cancer. – 2009. – Т. 124, № 12. – С. 2942-2947.

Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: cancer today. Lyon, France: International Agency for Research on Cancer 2020. https://gco.iarc.fr/today (accessed Mar 11, 2023)

How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? / S.Z. Lai, W.F. Li, L. Chen [и др.] // International Journal of Radiation Oncology - Biology - Physics.. – 2011. – Т. 80, № 3. – С. 661-668.

Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? / R. Guo, Y. Sun, X. L. Yu [и др.] // Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology.. – 2012. – Т. 104, № 3. – С. 294-299.

MAC-NPC Collaborative Group (2015). Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. / P. Blanchard, A. Lee, S. Marguet [и др.] // The Lancet. Oncology. – 2015. – Т. 16, № 6. – С. 645-655.

Oral hygiene and risk of nasopharyngeal carcinoma—a population-based case-control study in China. / Z. Liu, E.T. Chang, Q. Liu [и др.] // Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. – 2016. – Т. 25, № 8. – С. 1201-1207.

Prognostic significance of tumor volume in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy. / Z. Wu, R. F. Zeng, Y. Su [и др.] // Head & neck.. – 2013. – Т. 35, № 5. – С. 689-694.

Quantification of familial risk of nasopharyngeal carcinoma in a high-incidence area. / Z. Liu, E.T. Chang, Q. Liu [и др.] // Cancer. – 2017. – Т. 123, № 14. – С. 2716-2025.

Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. / M.K. Kam, P.M. Teo, R.M. Chau [и др.] // International Journal of Radiation Oncology - Biology - Physics.. – 2004. – Т. 60, № 5. – С. 1440-1450.

Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: results from a non-endemic cohort with 10-year follow-up. / L.R. Wu, X.M. Zhang, X.D. Xie [и др.] // Oral oncology. – 2019. – № 98. – С. 141-146.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2023